Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Inhibikase Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IKT
Nasdaq
8731
https://www.inhibikase.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Inhibikase Therapeutics Inc
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- Apr 18th, 2024 8:30 pm
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
- Apr 3rd, 2024 12:05 pm
Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
- Apr 2nd, 2024 3:51 pm
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript
- Apr 2nd, 2024 2:25 pm
Q4 2023 Inhibikase Therapeutics Inc Earnings Call
- Mar 29th, 2024 1:06 am
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
- Mar 27th, 2024 8:15 pm
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
- Mar 7th, 2024 1:30 pm
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
- Feb 28th, 2024 9:05 pm
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
- Feb 15th, 2024 2:55 pm
New Strong Buy Stocks for February 13th
- Feb 13th, 2024 11:47 am
Best Momentum Stocks to Buy for February 8th
- Feb 8th, 2024 3:00 pm
New Strong Buy Stocks for February 8th
- Feb 8th, 2024 11:38 am
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- Feb 7th, 2024 12:55 pm
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
- Jan 29th, 2024 2:05 pm
Best Momentum Stocks to Buy for January 26th
- Jan 26th, 2024 3:00 pm
New Strong Buy Stocks for January 26th
- Jan 26th, 2024 11:23 am
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
- Jan 22nd, 2024 5:00 pm
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
- Jan 16th, 2024 9:05 pm
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
- Dec 4th, 2023 1:35 pm
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
- Nov 14th, 2023 9:30 pm
Scroll